Synthorx to Present at the Chinese Society for Clinical Oncology Conference on Immunotherapy
12 Março 2019 - 9:00AM
Synthorx, Inc. (NASDAQ: THOR), a biotechnology company using a
first-of-its-kind Expanded Genetic Alphabet platform technology to
discover and develop optimized biologics for cancer and autoimmune
disorders, today announced the details of an oral presentation to
be held at the Chinese Society for Clinical Oncology (CSCO)
Conference on Immunotherapy, endorsed by the American Association
for Cancer Research (AACR), taking place in Shanghai, China.
The oral session will be held on March 22, 2019 from 15:30
China Standard Time.
Details of the presentation are as follows:
Title: THOR-707, an engineered not-alpha IL-2,
for the treatment of solid tumors induces strong immunological
responses in vivoPresenter: Gilles Dufour,
Ph.D.Session Date and Time: March 22, 2019; 15:30
China Standard Time (March 21, 2019; 23:30 Pacific
Time)Location: Main Conference Room, Le Meridien
Shanghai Minhang Hotel, Shanghai, China
A copy of the presentation slides will be posted to the
Investors & Media section of the company’s website at
https://www.synthorx.com at the time of the event, and will be
archived and available at that site.
About SynthorxSynthorx, Inc. is a biotechnology
company focused on prolonging and improving the lives of people
with cancer and autoimmune disorders. Synthorx’s proprietary,
first-of-its-kind Expanded Genetic Alphabet platform technology
expands the genetic code by adding a new DNA base pair and is
designed to create optimized biologics, referred to as
SynthorinsTM. A Synthorin is a protein optimized through
incorporation of novel amino acids encoded by the new DNA base pair
that enables site-specific modifications, which enhance the
pharmacological properties of these therapeutics. The company’s
lead product candidate, THOR-707, a variant of IL-2, is in
development in multiple tumor types as a single agent and in
combination with an immune checkpoint inhibitor. The company was
founded based on important discoveries in Dr. Floyd Romesberg’s lab
at The Scripps Research Institute. The company is headquartered in
La Jolla, Calif.
Forward-Looking Statements This press release
contains forward-looking statements about Synthorx as that term is
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. Statements in this
press release that are not purely historical are forward-looking
statements. Such forward-looking statements include, among other
things, preclinical data or plans underlying THOR-707 and the
development of Synthorx’s product candidates. Actual results could
differ from those projected in any forward-looking statements due
to numerous factors. Such factors include, among others, risks
associated with the process of discovering, developing and
commercializing drugs that are safe and effective for use as human
therapeutics and operating as a development stage company;
Synthorx’s ability to develop, initiate or complete preclinical
studies and clinical trials for, obtain approvals for and
commercialize any of its product candidates; changes in Synthorx’s
plans to develop and commercialize its product candidates; the
potential for any future clinical trials of THOR-707 or other
product candidates to differ from preliminary or expected results;
Synthorx’s ability to raise any additional funding it will need to
continue to pursue its business and product development plans;
regulatory developments in the United States and foreign countries;
Synthorx’s reliance on key third parties, including contract
manufacturers and contract research organizations; Synthorx’s
ability to obtain and maintain intellectual property protection for
its product candidates; the loss of key scientific or management
personnel; competition in the industry in which Synthorx operates;
and market conditions. These forward-looking statements are made as
of the date of this press release, and Synthorx assumes no
obligation to update the forward-looking statements, or to update
the reasons why actual results could differ from those projected in
the forward-looking statements. Investors should consult all of the
information set forth herein and should also refer to the risk
factor disclosure set forth in the documents the company files with
the SEC available at www.sec.gov.
Investor Contacts: Enoch Kariuki,
Pharm.D.Synthorx, Inc.ekariuki@synthorx.com 858-750-4750
Christina TartagliaStern Investor
Relationschristina.tartaglia@sternir.com212-362-1200
Media Relations Contact:Lauren FishCanale
Communicationslauren@canalecomm.com619-849-5386
Synthorx (NASDAQ:THOR)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Synthorx (NASDAQ:THOR)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024